The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The company said its molecular collection systems products saw the highest revenue growth during the quarter as product revenues rose 6 percent overall.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.